View Clinical Trial (Medical Research Study)

A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) - NCT00700427-27609(Clinical Trial 227930)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Raleigh
State:  
NC
Zip Code: 27609
Conditions: Attention Deficit Hyperactivity Disorder
Purpose: LYDO is a multi-center study that will enroll approximately 1925 adult outpatients with Attention Deficit/Hyperactivity Disorder (ADHD). Patients will receive under open label conditions atomoxetine up to 100 mg/day during the acute, open label part of the study. Those patients that meet the response criteria will continue the blind phase of the study up to a year. During that period patients that respond to atomoxetine will be randomized to continue the treatment with atomoxetine or with placebo (neither the patients or investigators know if patients receive atomoxetine or placebo).
Study summary:
Criteria: Inclusion Criteria: - Adults - Male or female - Must meet ADHD according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision™ (DSM-IV-TR™) criteria Exclusion Criteria: - Comorbidity with major psychiatric disorder - Clinically significant depression or anxiety - Patients with significant medical conditions - Current alcohol/drugs abuse/dependence - Concomitant excluded medications
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: June 11, 2010
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.